The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC).
Braz J Med Biol Res 2018 Jan 11;51(3):e7214. Epub 2018 Jan 11.
Departamento de Medicina Interna, Universidade Estadual do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.
A biosimilar is a biologic product that is similar to a reference biopharmaceutical product, the manufacturing process of which hinders the ability to identically replicate the structure of the original product, and therefore, it cannot be described as an absolute equivalent of the original medication. The currently available technology does not allow for an accurate copy of complex molecules, but it does allow the replication of similar molecules with the same activity. As biosimilars are about to be introduced in oncology practice, these must be evaluated through evidence-based medicine. Read More